Compounds > cimetidine sulfoxide
Page last updated: 2024-12-06

cimetidine sulfoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cimetidine sulfoxide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62949
CHEMBL ID3544520
CHEBI ID30731
SCHEMBL ID7192902
SCHEMBL ID11179015
MeSH IDM0105185

Synonyms (33)

Synonym
2-cyano-1-methyl-3-(2-{[(5-methyl-1h-imidazol-4-yl)methyl]sulfinyl}ethyl)guanidine
CHEBI:30731 ,
cimetidine sulfoxide
cimetidine s-oxide
54237-72-8
1-cyano-2-methyl-3-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfinyl]ethyl]guanidine
h6v3t9ug74 ,
unii-h6v3t9ug74
guanidine, n-cyano-n'-methyl-n''-(2-(((5-methyl-1h-imidazol-4-yl)methyl)sulfinyl)ethyl)-
n-cyano-n'-methyl-n-[2-((4-methyl-5-imidazolyl)methyl sulphinyl)ethyl]guanidine
HOJLJLYVNQFCRE-UHFFFAOYSA-N
SCHEMBL7192902
SCHEMBL11179015
skf-92452
(+/-)-cimetidine s-oxide
cimetidine sulfoxide, (+/-)-
guanidine, n-cyano-n'-methyl-n''-(2-(((4-methyl-1h-imidazol-5-yl)methyl)sulfinyl)ethyl)-
unii-e1296x9v0x
unii-6ve31s69b1
CHEMBL3544520
2-cyano-1-methyl-3-[2-[[(5-methyl-1h-imidazol-4-yl)methyl]sulphinyl]ethyl]guanidine (cimetidine sulphoxide)
Q27113965
cimetidine sulphoxide dihydrochloride
n-cyano-n''-methyl-n'-{2-[(4-methyl-1h-imidazol-5-yl)methanesulfinyl]ethyl}guanidine
DTXSID50969219
BS-52765
1-cyano-3-methyl-2-(2-(((4-methyl-1h-imidazol-5-yl)methyl)sulfinyl)ethyl)guanidine
CS-0128291
HY-136338
n-cyano-n''-methyl-n'-{2-[(5-methyl-1h-imidazol-4-yl)methanesulfinyl]ethyl}guanidine
2-cyano-1-methyl-3-[2-(5-methylimidazol-4-ylmethylsulphinyl)ethyl]guanidine
F77372
AKOS040756206

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"21 l/h per kg) with a consequent increase in half-life (24."( Dose-dependent pharmacokinetics of cimetidine in the rat.
Aarons, L; Adedoyin, A; Houston, JB, 1987)		0.27
" time data were analysed by non-linear least squares regression analysis to determine pharmacokinetic parameter estimates."( Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone.
Ashcraft, SM; Dyke, TM; Gerken, DF; Reed, SM; Sams, RA, 1997)		0.3

Bioavailability

ExcerptReferenceRelevance
" The proposed method is rapid, accurate and precise, and it should be useful for clinical, bioavailability and pharmacokinetic studies of cimetidine."( An improved high performance liquid chromatographic method for determination of cimetidine and its major metabolite in plasma.
Cervantes-Campos, C; Delgadillo-Valencia, MP; Girard-Cuesy, ME; León-Urrea, F; Montoya-Cabrera, MA, )		0.13
" The median (range) extent of intragastric bioavailability was 14."( Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone.
Ashcraft, SM; Dyke, TM; Gerken, DF; Reed, SM; Sams, RA, 1997)		0.3

Dosage Studied

ExcerptRelevanceReference
" This same dosage in obese individuals with normal serum creatinine values should result in the same average steady-state serum concentrations."( Cimetidine clearance in the obese.
Bauer, LA; Dellinger, EP; Edwards, WA; Ferreri, L; Jack, R; Raisys, V; Simonowitz, D; Wareing-Tran, C, 1985)		0.27
" Because of the 40% decrease in total clearance, dosage in cirrhotic patients with a history of PSE should be reduced to minimize the risk of CNS side effects associated with cimetidine."( Hepatic encephalopathy and altered cimetidine kinetics.
Bernhard, H; Schentag, JJ; Ziemniak, JA, 1983)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfoxideAn organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (60.00)18.7374
1990's2 (20.00)18.2507
2000's2 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.58 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		3.68100aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
famotidine
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.		1.98101,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
oxyphenbutazone
Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.		1.9910phenols;
pyrazolidines		antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		1.9910pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		1.9810aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
chlorine
Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.		2.0310diatomic chlorine;
gas molecular entity		bleaching agent
deoxycholic acid
Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.		2.0510bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid: An inhibitor of anion conductance including band 3-mediated anion transport.		1.9810
beta-sultam
beta-sultam: structure in first source		2.0310
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalopathy, Hepatic
[description not available]		01.9610
Cirrhosis, Liver
[description not available]		01.9610
Hepatic Encephalopathy
A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)		01.9610
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		01.9610
Cystic Fibrosis of Pancreas
[description not available]		01.9710
Cystic Fibrosis
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.		01.9710
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9610
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		01.9610